Inactivated human platelet lysate with psoralen: a new perspective for mesenchymal stromal cell production in Good Manufacturing Practice conditions

[1]  K. Drzewiecki,et al.  Pooled human platelet lysate versus fetal bovine serum-investigating the proliferation rate, chromosome stability and angiogenic potential of human adipose tissue-derived stem cells intended for clinical use. , 2013, Cytotherapy.

[2]  F. Fagioli,et al.  Validation of analytical methods in compliance with good manufacturing practice: a practical approach , 2013, Journal of Translational Medicine.

[3]  F. Rodeghiero,et al.  Production of human platelet lysate by use of ultrasound for ex vivo expansion of human bone marrow-derived mesenchymal stromal cells. , 2013, Cytotherapy.

[4]  S. Higgs,et al.  Photochemical inactivation of chikungunya virus in human apheresis platelet components by amotosalen and UVA light. , 2013, The American journal of tropical medicine and hygiene.

[5]  C. Prowse,et al.  Component pathogen inactivation: a critical review , 2013, Vox sanguinis.

[6]  Wei Li,et al.  Manufacturing mesenchymal stromal cells for phase I clinical trials. , 2013, Cytotherapy.

[7]  F. Trautinger,et al.  Photopheresis (extracorporeal photochemotherapy) , 2012, Photochemical & Photobiological Sciences.

[8]  A. Ignatius,et al.  GMP-Compliant Isolation and Large-Scale Expansion of Bone Marrow-Derived MSC , 2012, PloS one.

[9]  Armand Keating,et al.  Mesenchymal stromal cells: new directions. , 2012, Cell stem cell.

[10]  F. Fagioli,et al.  Validation of analytical methods in GMP: the disposable Fast Read 102® device, an alternative practical approach for cell counting , 2012, Journal of Translational Medicine.

[11]  A. Ignatius,et al.  Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identification of active components , 2012, Cytotherapy.

[12]  F. Fagioli,et al.  Multipotent Mesenchymal Stromal Stem Cell Expansion by Plating Whole Bone Marrow at a Low Cellular Density: A More Advantageous Method for Clinical Use , 2011, Stem cells international.

[13]  A. Gratwohl,et al.  Pathogen-inactivation of platelet components with the INTERCEPT Blood System ™: a cohort study. , 2011, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[14]  Lily Lin,et al.  Pathogen Inactivation of Platelet and Plasma Blood Components for Transfusion Using the INTERCEPT Blood SystemTM , 2011, Transfusion Medicine and Hemotherapy.

[15]  G. Lucchini,et al.  Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[16]  O. Korsgren,et al.  Photochemical pathogen inactivation of human serum enables its large‐scale application in clinical cell transplantation , 2010, Vox sanguinis.

[17]  E. Medico,et al.  Multipotent mesenchymal stem cells from amniotic fluid originate neural precursors with functional voltage-gated sodium channels. , 2009, Cytotherapy.

[18]  S. Meuth,et al.  Platelet derived bFGF mediates vascular integrative mechanisms of mesenchymal stem cells in vitro. , 2009, Journal of molecular and cellular cardiology.

[19]  J. Cazenave,et al.  Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La Réunion , 2009, Transfusion.

[20]  M. Blajchman,et al.  Protecting the blood supply from emerging pathogens: the role of pathogen inactivation. , 2009, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine.

[21]  S. Wagner,et al.  Evaluation of in vitro storage properties of prestorage pooled whole blood–derived platelets suspended in 100 percent plasma and treated with amotosalen and long‐wavelength ultraviolet light , 2009, Transfusion.

[22]  M. Steiert,et al.  Photochemical inactivation with amotosalen and long‐wavelength ultraviolet light of Plasmodium and Babesia in platelet and plasma components , 2008, Transfusion.

[23]  O. Ringdén,et al.  No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients , 2007, Haematologica.

[24]  M. Introna,et al.  Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts , 2007, Bone Marrow Transplantation.

[25]  Karl Kashofer,et al.  Human platelet lysate can replace fetal bovine serum for clinical‐scale expansion of functional mesenchymal stromal cells , 2007, Transfusion.

[26]  C. Lass‐Flörl,et al.  Prevention of transfusion of platelet components contaminated with low levels of bacteria: a comparison of bacteria culture and pathogen inactivation methods , 2007, Transfusion.

[27]  R. Tice,et al.  The pathogen reduction treatment of platelets with S-59 HCl (Amotosalen) plus ultraviolet A light: genotoxicity profile and hazard assessment. , 2007, Mutation research.

[28]  D. G. Halme,et al.  FDA regulation of stem-cell-based therapies. , 2006, The New England journal of medicine.

[29]  L. Mazzini,et al.  Autologous mesenchymal stem cells: clinical applications in amyotrophic lateral sclerosis , 2006, Neurological research.

[30]  L. Corash,et al.  Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long‐wavelength ultraviolet light , 2005, Transfusion.

[31]  M. Pittenger,et al.  Human mesenchymal stem cells modulate allogeneic immune cell responses. , 2005, Blood.

[32]  H. Schöler,et al.  Oct4 is required for primordial germ cell survival , 2004, EMBO reports.

[33]  Shu-Ching Hsu,et al.  Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[34]  J. Nichols,et al.  Functional Expression Cloning of Nanog, a Pluripotency Sustaining Factor in Embryonic Stem Cells , 2003, Cell.

[35]  P. Ljungman,et al.  Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. , 2003, Blood.

[36]  L. Muul,et al.  Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[37]  N. Fisk,et al.  Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. , 2001, Blood.

[38]  P. Mannucci,et al.  The transfusion-associated transmission of parvovirus B19. , 1999, Transfusion medicine reviews.

[39]  M. Pittenger,et al.  Multilineage potential of adult human mesenchymal stem cells. , 1999, Science.

[40]  L. Corash,et al.  Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. , 1998, Blood.

[41]  J. Hearst,et al.  Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long‐wavelength ultraviolet light , 1997, Transfusion.

[42]  J. Saldanha,et al.  Detection of human parvovirus B19 DNA in plasma pools and blood products derived from these pools: implications for efficiency and consistency of removal of B19 DNA during manufacture , 1996, British journal of haematology.

[43]  J. E. Turner,et al.  BacT/Alert: an automated colorimetric microbial detection system , 1990, Journal of clinical microbiology.

[44]  H. Hendrickson.  Prevention of what? , 1983, Journal of the American Optometric Association.

[45]  D. Prockop,et al.  Mesenchymal Stem/Stromal Cells (MSCs): Role as Guardians of Inflammation. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[46]  Karin Tarte,et al.  Good manufacturing practices production of mesenchymal stem/stromal cells. , 2011, Human gene therapy.

[47]  A. Reinisch,et al.  Platelet-derived growth factors for GMP-compliant propagation of mesenchymal stromal cells. , 2009, Bio-medical materials and engineering.

[48]  P. Bourin,et al.  Producing MSC according GMP: process and controls. , 2008, Bio-medical materials and engineering.

[49]  R. Raymond,et al.  S‐59 HCl(Amotosalen)と紫外線A照明による血小板の病原体減少処置:遺伝毒性様相と有害性評価 , 2007 .

[50]  R. Handgretinger,et al.  Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM. , 2006, Cytotherapy.

[51]  W. Piacibello,et al.  Isolation of human mesenchymal stem cells: bone marrow versus umbilical cord blood. , 2001, Haematologica.